Mesenchymal stem cell therapy: Two steps forward, one step back
By J. Ankrum, J. Karp. Trends in Molecular Medicine, 2010
609 citations recorded by the source corpus.
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has not been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.
Subfields: Genetics, Rehabilitation, Surgery
View Paper: https://www.semanticscholar.org/paper/1c5ed6d83a4d6a1c0b2900c395664c1f4c173a65
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Rehabilitation
In Surgery
Citations in the corpus
- Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease (2012, background): “…and immunomodulatory properties of MSCs represent a primary mechanism of therapeutic action that is referred to in many current clinical trials (Ankrum and Karp, 2010; Wollert and Drexler, 2010), it is important to note that these functions of MSCs have not yet been optimized in preclinical…”